API | vofopitant

vofopitant Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Vofopitant (GR205171) is a drug which acts as an NK1 receptor antagonist. It has antiemetic effects as with other NK1 antagonists, and also shows anxiolytic actions in animals. It was studied for applications such as the treatment of social phobia and post-traumatic stress disorder, but did not prove sufficiently effective to be marketed. ^Wikipedia

Chemistry

SMILES: COc1ccc(-n2nnnc2C(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1
InChIKey: XILNRORTJVDYRH-HKUYNNGSSA-N
Mol. Mass: 432.45
ALogP: 3.27 Partition coefficient
ChEMBL Molecule:
vofopitant

More Chemistry

Pharmacology

Mechanism of Action:
- Substance-P receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

gr205171 | gr 205171 | gr-205171 | gr 226206 | l-796,325 | n-((2-methoxy-5-(5-(trifluoromethyl)-1h-tetrazol-1-yl)phenyl)methyl)-2-phenyl-3-piperidinamine | vofopitant

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Bipolar Disorder (Phase 1)

Sleep Initiation and Maintenance Disorders (Phase 2)

Stress Disorders, Post-Traumatic (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 3
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue